Wolfgang Albrecht

This inventor holds 44 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 49 EPO patents, primarily in Protein Kinase Inhibitors. Top assignees: Ratiopharm Gmbh, Maschinenfabrik Reinhausen Gmbh, Heparegenix Gmbh. Active years: 1996-2026.

USPTO Granted Patents = 44 (Patent Applications = 13)

% Patents Active = 54.5

CIPO Patents = 3

EPO Patents = 49 (Patent Applications = 58)

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 72(Granted Patents)

Location History:

Teltow, DE (2007 - 2013)
Wenzenbach, DE (1996 - 2018)
Ulm, DE (2008 - 2024)

Company Filing History:

Maschinenfabrik Reinhausen Gmbh

C-A-I-R Biosciences Gmbh

patents

5. 2 out of 74

Gkss-Forschungszentrum Geesthacht Gmbh

Siemens Aktiengesellschaft

patents

8. 1 out of 34

Helmholtz-Zentrum Geesthacht Zentrum Fur Material Und Kustenforschung Gmbh

patents

9. 1 out of 54

Teva Pharmaceuticals International Gmbh

patents

10. 1 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2026

Loading Chart...

Areas of Expertise:

MKK4 Inhibitors

Liver Regeneration

Hepatocyte Death

Quinolin Derivatives

Co-Crystals

Solid State Forms

Prodrugs

Tap Changer

Polyimide Microparticles

Pharmaceutical Agents

Imidazole Derivatives

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12749634 - On-load tap changer and tap-changing transformer having an on-load tap changer (2026-09-29),

2. 12643895 - Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2026-06-02),

3. 12466826 - 3-benzoyl-1H-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases (2025-11-11),

4. 12264158 - Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2025-04-01),

5. 11912701 - Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2024-02-27),

6. 11858927 - Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2024-01-02),

7. 11731968 - Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2023-08-22),

8. 11040027 - Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2021-06-22),

9. 10745357 - Process for preparing quinolin-2-yl-phenylamine derivatives and their salts (2020-08-18),

10. 10669275 - Methods of preparing co-crystals of ibrutinib with carboxylic acids (2020-06-02),

11. 10526326 - Crystalline form and acetic acid adducts of palbociclib (2020-01-07),

12. 10464903 - Process for preparing quinolin-2-yl-phenylamine derivatives and their salts (2019-11-05),

13. 10377758 - Co-crystals of ibrutinib with carboxylic acids (2019-08-13),

14. 10214553 - Solid state forms of sofosbuvir (2019-02-26),

15. 10153101 - Switching system with preselector (2018-12-11),

Title: Wolfgang Albrecht: A Pioneer in Liver Regeneration Research

Introduction

Wolfgang Albrecht, based in Ulm, Germany, is a prolific inventor with an impressive portfolio of 26 patents. His work primarily focuses on the development of innovative compounds aimed at promoting liver regeneration and addressing challenges related to hepatocyte death.

Latest Patents

Albrecht's latest patents include groundbreaking inventions related to protein kinase inhibitors. One such invention involves compounds that are selective inhibitors of MKK4 (mitogen-activated protein kinase kinase 4). These compounds are designed to promote liver regeneration or reduce hepatocyte death. The particular formula allows for selective inhibition of protein kinase MKK4 over JNK and MKK7. He has also developed pyrazolo-pyridine compounds that offer similar benefits while being applicable in treating conditions like osteoarthritis, rheumatoid arthritis, and certain central nervous system-related diseases.

Career Highlights

Throughout his career, Wolfgang Albrecht has contributed significantly to the field of biotechnology. He has held notable positions within companies such as Ratiopharm GmbH and Heparegenix GmbH, where he has leveraged his expertise to innovate and develop new medical therapies.

Collaborations

Albrecht has collaborated with talented professionals in his field, including colleagues Roland Selig and Sebastian Rabe. Their collective efforts aim to enhance the understanding and treatment of liver-related conditions, furthering the advancement of medical science.

Conclusion

Wolfgang Albrecht's contributions to liver regeneration research underscore the potential of innovative compounds in addressing critical health issues. His extensive research and development efforts reflect his commitment to improving medical outcomes through targeted inventions and collaborations.